GlassScriptPhysician profile
Shirley Shuster
NPI 1427869874
$1,189.95
in general payments reported to CMS, 2019-2025
19 companies · $1,190 in 2025
The $1,190 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,189.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $343.53 | 2025 | Ozempic, Wegovy |
| Neurocrine Biosciences, INC. | $136.51 | 2025 | |
| Xeris Pharmaceuticals, INC. | $89.79 | 2025 | Recorlev, Gvoke Hypopen |
| Sequel Med Tech, LLC | $69.00 | 2025 | Twiist |
| Abbvie INC. | $66.27 | 2025 | |
| Beta Bionics, INC. | $66.14 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Lilly USA, LLC | $65.08 | 2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $64.20 | 2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.70 | 2025 | Jardiance |
| Antares Pharma, INC. | $37.48 | 2025 | Xyosted |
| Recordati_rare_diseases_inc. | $28.90 | 2025 | Isturisa |
| Sanofi-Aventis U.S. LLC | $27.74 | 2025 | |
| Kyowa Kirin, INC. | $25.06 | 2025 | |
| Ibsa Pharma INC. | $24.68 | 2025 | Tirosint, Flector, Licart |
| Ascendis Pharma Endocrinology INC | $24.51 | 2025 | Yorvipath |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $22.58 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $22.04 | 2025 | Imcivree |
| Gilead Sciences, INC. | $19.26 | 2025 | |
| Cequr Corporation | $16.48 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shirley Shuster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.